GlassScriptPhysician profile
Kendra G Worden
NPI 1972772259
$1,046.26
in general payments reported to CMS, 2019-2025
11 companies · $357 in 2025
The $357 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $198 · 2022: $125 · 2023: $140 · 2024: $227 · 2025: $357.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $408 · Education: $315.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $408.33 |
| Education | $314.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $222.09 | 2024-2025 | Trodelvy |
| Amgen INC. | $198.00 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $125.00 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $102.46 | 2023 | Reblozyl |
| Glaxosmithkline, LLC. | $101.15 | 2025 | Ojjaara |
| Janssen Biotech, INC. | $99.99 | 2024 | Rybrevant |
| Seagen INC. | $99.99 | 2025 | |
| Siemens Medical Solutions USA, INC. | $32.86 | 2024 | Aria Radiation Therapy Management Software |
| Novocure INC. | $27.43 | 2025 | Optune Gio |
| Mirati Therapeutics, INC. | $21.00 | 2023 | Krazati |
| Genentech USA, INC. | $16.29 | 2023 | Lunsumio, Columvi |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kendra Worden listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.